Canada has approved the use of DSM-Firmenich’s Parsol Shield UV filter in multifunctional skin care and other cosmetic products.
Health Canada has officially added Parsol Shield (Bemotrizinol) to the Secondary Sunscreen Monograph at concentrations up to 6%.
Parsol Shield has long been permitted under Canada’s Primary Sunscreen Monograph, where sun protection is the main intended function of the product.
Until now, the ingredient had not been listed for use in products where sun protection plays a secondary role, such as daily-wear cosmetics and multifunctional skin care products.
The updated monograph closes this gap by permitting Parsol Shield in a wider array of formulations.
“This milestone aligns with DSM-Firmenich’s ongoing efforts in the United States to secure FDA approval of Parsol Shield as a sunscreen active ingredient,” said Amy Ethier, DSM’s North America beauty and care regulatory affairs manager.
“Health Canada’s decision to update the monograph reflects a strengthened industry alignment and reinforces the strong safety and efficacy profile of Parsol Shield as a highly photostable, broad‑spectrum UVA/UVB filter,” she added.
The updated monograph will enable broader use of Parsol Shield in sunscreen‑containing products sold in Canada, offering formulators enhanced flexibility to develop innovative formats that meet evolving consumer needs.
This regulatory progression supports DSM-Firmenich’s commitment to advancing high-performance UV filters while expanding market opportunities for its customers.
